ABSTRACT
In late 2019, the world witnessed the emergence of one of the most alarming pandemics recorded in the Contemporary Age, Covid-19. The new coronavirus is responsible for causing the disease Covid-19 and it has since spread to over 180 countries. As the disease spreads over the world, it has become a global pandemic, threatening global public health, and presenting a huge threat to global civilization. To oppose and prevent the spread of COVID-19, everyone should be well informed on the disease's constantly changing status. To accomplish this purpose, a COVID-19 analytical tracker was developed using PowerBI to provide the most up-to-date sickness status as well as critical analytical insights. The Covid tracker is intended for the general public who lack specialized statistical knowledge. It tries to express insights using a variety of basic and succinct data visualizations backed up by reputable data sources. The purpose of this paper is to describe the key strategies used to create the insights presented on the tracker, which include data retrieval, normalization techniques, and ML/DL models. In addition to explaining the facts and justifications for the approaches used, the paper includes several major discoveries made in relation to COVID-19 utilizing the methodologies. © 2022 IEEE.
ABSTRACT
Introduction: Remdesivir and Tocilizumab are two experimental drugs used in severely ill COVID-19 patients. Various clinical trials studying these drugs are giving conflicting results. Our aim is to study these two drugs and share the experience in our setting. Methods: Our Study is a retrospective analysis of Clinico-laboratory details and outcome of three groups of patients who were given either (i) Remdesivir or (ii) Tocilizumab or (iii)both Remdesivir and Tocilizumab . We compared the outcome of these patients with other patients who did not receive either of these drugs, when it was not available or not introduced as experimental drugs earlier in treatment guidelines. Results: Out of a total of 521 patients, in the above three groups who received either or both Remdesivir or Tocilizumab, 334 survived. Out of 214 patients who did not receive any of the two drugs only 74 survived. The outcome was better individually for all the three groups of patients receiving either or both of the drugs as compared to neither of the drugs.(p <0.01) Conclusion: Remdesivir and Tocilizumab were useful drugs in treatment of severely ill covid -19 patients as compared with the patients who did not receive any of the above drugs. © 2021 Journal of Association of Physicians of India. All rights reserved.